Transfer Pricing & Tax Issues
Few industries are subject to more complex transfer pricing challenges than pharmaceuticals. Pharmaceutical companies are twice as likely as other companies to face an adjustment resulting from an audit: when disputes arise, the financial exposure can be staggering. Factors influencing this landscape include:
- the rise of generic drugs
- regulatory issues relating to intellectual property
- new or amended transfer pricing legislation
- increased scrutiny by tax authorities
- increased information sharing across borders.
All of the above make it important for pharmaceutical companies and their counsel to have access to consultants who combine sophisticated financial and economic analysis with deep industry expertise.
Our experience encompasses transfer pricing challenges in connection with health care intellectual property litigation, as well as challenges from tax authorities in the United States and abroad. Our experts have presented their findings to tax authorities in numerous jurisdictions around the world.
Analysis Group has significant experience in providing transfer pricing analysis and tax consulting to health care companies. Clients use our work in connection with income tax audits and in litigation.
SPOTLIGHT ON AN EXPERT
Academic affiliate Lorraine Eden is an internationally known expert in strategic transfer pricing; foreign direct investment in tax havens and corrupt economies; and MNE strategies for coping with liability of foreignness.
Our work is frequently published in prestigious peer-reviewed journals and leading business and industry publications.